StockNews.com upgraded shares of ProAssurance (NYSE:PRA – Free Report) from a hold rating to a buy rating in a research report sent to investors on Thursday.
A number of other equities research analysts have also commented on PRA. Piper Sandler lowered ProAssurance from an “overweight” rating to a “neutral” rating and set a $18.00 target price on the stock. in a research report on Monday, November 11th. Truist Financial boosted their target price on shares of ProAssurance from $14.00 to $18.00 and gave the company a “hold” rating in a research report on Tuesday, November 12th.
View Our Latest Report on ProAssurance
ProAssurance Stock Performance
Institutional Investors Weigh In On ProAssurance
Institutional investors have recently bought and sold shares of the company. Point72 Hong Kong Ltd purchased a new position in shares of ProAssurance in the second quarter valued at approximately $28,000. nVerses Capital LLC purchased a new stake in ProAssurance in the third quarter valued at $44,000. Innealta Capital LLC purchased a new position in shares of ProAssurance during the 2nd quarter worth $69,000. Point72 Asia Singapore Pte. Ltd. raised its holdings in ProAssurance by 94.3% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 8,347 shares of the insurance provider’s stock valued at $126,000 after buying an additional 4,052 shares during the period. Finally, Susquehanna Fundamental Investments LLC acquired a new position in ProAssurance in the second quarter valued at about $166,000. 85.58% of the stock is currently owned by institutional investors and hedge funds.
ProAssurance Company Profile
ProAssurance Corporation, through its subsidiaries, provides property and casualty insurance, and reinsurance products in the United States. The company operates through Specialty Property and Casualty, Workers’ Compensation Insurance, and Segregated Portfolio Cell Reinsurance segments. It offers professional liability insurance to healthcare providers and institutions, and attorneys and their firms; medical technology liability insurance to medical technology and life sciences companies; and custom alternative risk solutions, including assumed reinsurance, loss portfolio transfers, and captive cell programs for healthcare professional liability insureds.
Featured Articles
- Five stocks we like better than ProAssurance
- ESG Stocks, What Investors Should Know
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Top 3 ETFs to Hedge Against Inflation in 2025
- About the Markup Calculator
- These 3 Chip Stock Kings Are Still Buys for 2025
Receive News & Ratings for ProAssurance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProAssurance and related companies with MarketBeat.com's FREE daily email newsletter.